Skip to main content Skip to search Skip to main navigation

PANGEA XV: Worldwide Campaign against Falsified and Illegally Imported Medicinal Products

From 23 to 30 June 2022, Interpol conducted its 15th globally coordinated operation PANGEA against the illegal online trade of medicines. From fake COVID-19 tests to doping substances or narcotics, the range of illegal shipments was broad.

This year, 94 countries were involved in the operation. A total of more than 3 million units were seized worldwide, including more than 7,800 illegal and counterfeit medicines and medical products. The found counterfeit medicines were mostly produced in Asian countries with counterfeit erectile stimulants originating in India.

During the week, law enforcement

  • Investigated more than 4,000 web links, mainly from social media platforms and messaging apps
  • Shut down or removed more than 4,000 web links containing adverts for illicit products
  • Inspected nearly 3,000 packages and 280 postal hubs at airports, borders and mail distribution or cargo mail centres
  • Opened more than 600 new investigations and issued more than 200 search warrants

While results are still coming in from countries, enforcement actions have already disrupted the activities of at least 36 organized crime groups.

About 40 % of all products seized were counterfeit or unapproved erectile stimulants. Law enforcement agencies in Australia, Argentina, Malaysia, and the United States also seized more than 317,000 unapproved COVID-19 test kits. The seizures in the US alone have an estimated value of nearly USD 3 million.

If you are interested in more information on the global action please click here.


Source:

Interpol: PANGEA XV

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
Previous
Next